سعر مفاستاسين 20/500 مجم 10 اقراص 2026

Mvastacin 20/500 mg, 10 extended-release film-coated tablets (Al Esraa Pharmaceutical Optima, Egypt): fixed combination of simvastatin 20 mg and niacin (nicotinic acid) 500 mg. Closest historical US reference is SIMCOR (niacin ER/simvastatin) which included a 500 mg/20 mg strength; US approval of niacin/statin combinations was later withdrawn for lack of incremental cardiovascular benefit.

• Adjunct to diet to reduce elevated total-C, LDL-C, Apo B, non-HDL-C, TG, or to increase HDL-C in primary hypercholesterolemia and mixed dyslipidemia when simvastatin or niacin ER monotherapy is considered inadequate (historical US SIMCOR label).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions with historical SIMCOR included flushing, headache, back pain, diarrhea, nausea and pruritus (incidence >3%).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Active liver disease or unexplained persistent hepatic transaminase elevations; active peptic ulcer disease; arterial bleeding; pregnancy (or women who may become pregnant); hypersensitivity to product components (historical US SIMCOR label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis risk increases with higher doses, age ≥65, hypothyroidism, renal impairment, and concomitant cyclosporine, danazol, gemfibrozil, amiodarone, verapamil or potent CYP3A4 inhibitors (historical US SIMCOR label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Do not substitute for equivalent doses of immediate-release (crystalline) niacin; flushing is common with niacin ER. Monitor liver enzymes (historical US SIMCOR label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Important regulatory context: the US FDA later withdrew approval of extended-release niacin in combination with a statin for cardiovascular risk reduction after large outcome trials failed to show incremental benefit when LDL-C was already well controlled on a statin. This US regulatory history does not by itself establish the current Egyptian regulatory status of Mvastacin.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone)MajorIncrease simvastatin exposure; combination with SIMCOR should not be used (historical US label).DailyMed (U.S. National Library of Medicine)
• Gemfibrozil / fenofibrateMajorCombination with SIMCOR should be avoided (myopathy risk) (historical US label).DailyMed (U.S. National Library of Medicine)

• SIMCOR was pregnancy category X and contraindicated in women who are or may become pregnant; lipid-lowering drugs offer no benefit during pregnancy and cholesterol derivatives are needed for fetal development (historical US label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.